Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Ladenburg Thalmann 2021 Virtual Healthcare Conference (Virtual)Presentation Date:                July 13, 2021Presentation Time:                11:00 am ETWebcast Link:                        https://wsw.com/webcast/ladenburg7/wint/2453238

A replay of the presentation will be available on the Investor Page of the company’s website (www.windtreetx.com).

About Windtree TherapeuticsWindtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company's website at www.windtreetx.com.

Contact Information:Monique KosseLifeSci Advisors212.915.3820 or [email protected]

Media contact:Andrew MielachLifeSci Communications646.876.5868 or [email protected]

Source: Windtree Therapeutics

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
• 2026’s Top Window Covering Trends, and the Sister-Owned Store Carrying Them All